Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) shares rose 1.9% during mid-day trading on Monday . The company traded as high as $11.62 and last traded at $11.53, with a volume of 89,268 shares changing hands. The stock had previously closed at $11.31.

SCMP has been the subject of a number of analyst reports. Maxim Group reissued a “buy” rating and issued a $26.00 price target on shares of Sucampo Pharmaceuticals in a report on Sunday, May 1st. Guggenheim reissued a “buy” rating and issued a $29.00 price target on shares of Sucampo Pharmaceuticals in a report on Wednesday, May 4th. Mizuho reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Wednesday, May 4th. WallachBeth Capital raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Thursday, May 5th. Finally, Roth Capital reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Tuesday, July 12th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $19.67.

The stock has a market capitalization of $491.89 million and a PE ratio of 40.32. The company’s 50-day moving average is $11.55 and its 200-day moving average is $11.52.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.01. The firm had revenue of $52 million for the quarter, compared to analysts’ expectations of $48.33 million. During the same quarter in the prior year, the business earned $0.21 EPS. The company’s quarterly revenue was up 49.1% compared to the same quarter last year. On average, analysts predict that Sucampo Pharmaceuticals Inc. will post $1.02 earnings per share for the current year.

A hedge fund recently raised its stake in Sucampo Pharmaceuticals stock. Systematic Financial Management LP boosted its position in Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) by 18.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 101,745 shares of the biopharmaceutical company’s stock after buying an additional 15,590 shares during the period. Systematic Financial Management LP owned 0.23% of Sucampo Pharmaceuticals worth $1,759,000 at the end of the most recent quarter.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.